{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:22:34Z","timestamp":1766524954447,"version":"3.48.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100019266","name":"Korea Medical Device Development Fund","doi-asserted-by":"publisher","award":["RS-2020-KD000038"],"award-info":[{"award-number":["RS-2020-KD000038"]}],"id":[{"id":"10.13039\/100019266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"DOI":"10.1007\/s11657-025-01560-1","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T08:25:09Z","timestamp":1752567909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative outcomes of denosumab and zoledronic acid discontinuation in hip fracture surgery: a nationwide database study"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3114-6045","authenticated-orcid":false,"given":"Seok Ha","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1589-1239","authenticated-orcid":false,"given":"Yeon Ju","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-4229","authenticated-orcid":false,"given":"Seung Beom","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"1560_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3390\/jpm11050341","volume":"11","author":"R Dobre","year":"2021","unstructured":"Dobre R, Niculescu DA, Petca RC, Popescu RI, Petca A, Poian\u0103 C (2021) Adherence to anti-osteoporotic treatment and clinical implications after hip fracture: a systematic review. J Pers Med 11:341. https:\/\/doi.org\/10.3390\/jpm11050341","journal-title":"J Pers Med"},{"key":"1560_CR2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.injury.2008.03.022","volume":"39","author":"S Haleem","year":"2008","unstructured":"Haleem S, Lutchman L, Mayahi R, Grice JE, Parker MJ (2008) Mortality following hip fracture: trends and geographical variations over the last 40 years. Injury 39:1157\u20131163. https:\/\/doi.org\/10.1016\/j.injury.2008.03.022","journal-title":"Injury"},{"key":"1560_CR3","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809. https:\/\/doi.org\/10.1056\/NEJMoa074941","journal-title":"N Engl J Med"},{"key":"1560_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1359\/jbmr.090704","volume":"25","author":"CS Col\u00f3n-Emeric","year":"2010","unstructured":"Col\u00f3n-Emeric CS, Mesenbrink P, Lyles KW et al (2010) Potential mediators of the mortality reduction with Zoledronic acid after hip fracture. J Bone Miner Res 25:91\u201397. https:\/\/doi.org\/10.1359\/jbmr.090704","journal-title":"J Bone Miner Res"},{"key":"1560_CR5","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5371\/hp.2022.34.4.191","volume":"34","author":"YK Oh","year":"2022","unstructured":"Oh YK, Moon NH, Shin WC (2022) Management of osteoporosis medication after osteoporotic fracture. Hip Pelvis 34:191\u2013202. https:\/\/doi.org\/10.5371\/hp.2022.34.4.191","journal-title":"Hip Pelvis"},{"key":"1560_CR6","doi-asserted-by":"publisher","first-page":"116216","DOI":"10.1016\/j.bone.2021.116216","volume":"154","author":"T-W Tai","year":"2022","unstructured":"Tai T-W, Li CC, Huang CF, Chan WP, Wu CH (2022) Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality: a nationwide population study. Bone 154:116216. https:\/\/doi.org\/10.1016\/j.bone.2021.116216","journal-title":"Bone"},{"key":"1560_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12877-019-1278-9","volume":"19","author":"SF Yu","year":"2019","unstructured":"Yu SF, Cheng JS, Chen YC et al (2019) Adherence to anti-osteoporosis medication associated with lower mortality following hip fracture in older adults: a nationwide propensity score-matched cohort study. BMC Geriatr 19:290. https:\/\/doi.org\/10.1186\/s12877-019-1278-9","journal-title":"BMC Geriatr"},{"key":"1560_CR8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677\u2013692. https:\/\/doi.org\/10.1016\/j.bone.2010.11.020","journal-title":"Bone"},{"key":"1560_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"1560_CR10","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Teglbj\u00e6rg CS, Langdahl BL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97:3161\u20133169. https:\/\/doi.org\/10.1210\/jc.2012-1569","journal-title":"J Clin Endocrinol Metab"},{"key":"1560_CR11","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00198-024-07118-0","volume":"35","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi T, Morimoto T, Ito K, Mawatari M, Shimazaki T (2024) Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials. Osteoporos Int 35:1377\u20131393. https:\/\/doi.org\/10.1007\/s00198-024-07118-0","journal-title":"Osteoporos Int"},{"key":"1560_CR12","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1007\/s00198-013-2395-5","volume":"24","author":"YK Lee","year":"2013","unstructured":"Lee YK, Ha YC, Choi HJ et al (2013) Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int 24:2887\u20132892. https:\/\/doi.org\/10.1007\/s00198-013-2395-5","journal-title":"Osteoporos Int"},{"key":"1560_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1532-5415.2010.02769.x","volume":"58","author":"LA Jennings","year":"2010","unstructured":"Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ (2010) Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 58:650\u2013657. https:\/\/doi.org\/10.1111\/j.1532-5415.2010.02769.x","journal-title":"J Am Geriatr Soc"},{"key":"1560_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00198-012-2024-8","volume":"24","author":"L Bondo","year":"2013","unstructured":"Bondo L, Eiken P, Abrahamsen B (2013) Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients\u2014a nationwide register-based open cohort study. Osteoporos Int 24:245\u2013252. https:\/\/doi.org\/10.1007\/s00198-012-2024-8","journal-title":"Osteoporos Int"},{"key":"1560_CR15","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00198-017-4009-0","volume":"28","author":"JA Kanis","year":"2017","unstructured":"Kanis JA, Cooper C, Rizzoli R et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28:2023\u20132034. https:\/\/doi.org\/10.1007\/s00198-017-4009-0","journal-title":"Osteoporos Int"},{"key":"1560_CR16","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s40265-021-01587-x","volume":"81","author":"LPB Elbers","year":"2021","unstructured":"Elbers LPB, Raterman HG, Lems WF (2021) Bone mineral density loss and fracture risk after discontinuation of anti-osteoporotic drug treatment: a narrative review. Drugs 81:1645\u20131655. https:\/\/doi.org\/10.1007\/s40265-021-01587-x","journal-title":"Drugs"},{"key":"1560_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","volume":"21","author":"AS S\u00f8lling","year":"2023","unstructured":"S\u00f8lling AS, Tsourdi E, Harsl\u00f8f T, Langdahl BL (2023) Denosumab discontinuation. Curr Osteoporos Rep 21:95\u2013103. https:\/\/doi.org\/10.1007\/s11914-022-00771-6","journal-title":"Curr Osteoporos Rep"},{"key":"1560_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM et al (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222\u2013229. https:\/\/doi.org\/10.1016\/j.bone.2008.04.007","journal-title":"Bone"},{"key":"1560_CR19","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/jbmr.448","volume":"26","author":"JP Brown","year":"2011","unstructured":"Brown JP, Dempster DW, Ding B et al (2011) Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. J Bone Miner Res 26:2737\u20132744. https:\/\/doi.org\/10.1002\/jbmr.448","journal-title":"J Bone Miner Res"},{"key":"1560_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/jcm10010152","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10:152. https:\/\/doi.org\/10.3390\/jcm10010152","journal-title":"J Clin Med"},{"key":"1560_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","volume":"29","author":"MB Zanchetta","year":"2018","unstructured":"Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR (2018) Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos Int 29:41\u201347. https:\/\/doi.org\/10.1007\/s00198-017-4242-6","journal-title":"Osteoporos Int"},{"key":"1560_CR22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"key":"1560_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243\u2013254. https:\/\/doi.org\/10.1002\/jbmr.1494","journal-title":"J Bone Miner Res"},{"key":"1560_CR24","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","volume":"19","author":"JR Curtis","year":"2008","unstructured":"Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19:1613\u20131620. https:\/\/doi.org\/10.1007\/s00198-008-0604-4","journal-title":"Osteoporos Int"},{"key":"1560_CR25","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","volume":"32","author":"JA Kim","year":"2017","unstructured":"Kim JA, Yoon S, Kim LY, Kim DS (2017) Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 32:718\u2013728. https:\/\/doi.org\/10.3346\/jkms.2017.32.5.718","journal-title":"J Korean Med Sci"},{"key":"1560_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4055\/cios23282","volume":"16","author":"SH Kim","year":"2024","unstructured":"Kim SH, Jang SY, Cha Y, Kim BY, Lee HJ, Kim GO (2024) Comparative interrupted time series analysis of direct medical expense and length of stay in elderly patients with femoral neck fractures who underwent total hip arthroplasty and hemiarthroplasty: a real world nationwide database study. Clin Orthop Surg 16:217\u2013229. https:\/\/doi.org\/10.4055\/cios23282","journal-title":"Clin Orthop Surg"},{"key":"1560_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/jbmr\/zjae070","volume":"39","author":"C Park","year":"2024","unstructured":"Park C, Kim C, Park RW, Jeon JY (2024) Comparative effectiveness and safety outcomes between denosumab and bisphosphonate in South Korea. J Bone Miner Res 39:835\u2013843. https:\/\/doi.org\/10.1093\/jbmr\/zjae070","journal-title":"J Bone Miner Res"},{"key":"1560_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.11005\/jbm.2022.29.2.83","volume":"29","author":"JY Kang","year":"2022","unstructured":"Kang JY, Choi L, Johnson B, Yang H (2022) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in South Korea. J Bone Metab 29:83\u201392. https:\/\/doi.org\/10.11005\/jbm.2022.29.2.83","journal-title":"J Bone Metab"},{"key":"1560_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension. J Bone Miner Res 33:190\u2013198. https:\/\/doi.org\/10.1002\/jbmr.3337","journal-title":"J Bone Miner Res"},{"key":"1560_CR30","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/jbmr.3370","volume":"33","author":"O Lamy","year":"2018","unstructured":"Lamy O, Gonzalez-Rodriguez E (2018) Underestimation of vertebral fractures after denosumab discontinuation. J Bone Miner Res 33:547\u2013547. https:\/\/doi.org\/10.1002\/jbmr.3370","journal-title":"J Bone Miner Res"},{"key":"1560_CR31","doi-asserted-by":"publisher","first-page":"115150","DOI":"10.1016\/j.bone.2019.115150","volume":"130","author":"Tripto-Shkolnik L, Fund N, Rouach V, Chodick G, Shalev V, Goldshtein I","year":"2020","unstructured":"Tripto-Shkolnik L, Fund N, Rouach V, Chodick G, Shalev V, Goldshtein I (2020) Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider. Bone 130:115150. https:\/\/doi.org\/10.1016\/j.bone.2019.115150","journal-title":"Bone"},{"key":"1560_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"key":"1560_CR33","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.81","volume":"25","author":"E Seeman","year":"2010","unstructured":"Seeman E, Delmas PD, Hanley DA (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25:1886\u20131894. https:\/\/doi.org\/10.1002\/jbmr.81","journal-title":"J Bone Miner Res"},{"key":"1560_CR34","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/joim.13354","volume":"290","author":"SH Fu","year":"2021","unstructured":"Fu SH, Wang CY, Hung CC et al (2021) Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: a population-based cohort study. J Intern Med 290:1194\u20131205. https:\/\/doi.org\/10.1111\/joim.13354","journal-title":"J Intern Med"},{"key":"1560_CR35","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/(SICI)1096-8644(200004)111:4<519::AID-AJPA7>3.0.CO;2-7","volume":"111","author":"DM Mulhern","year":"2000","unstructured":"Mulhern DM (2000) Rib remodeling dynamics in a skeletal population from Kulubnarti, Nubia. Am J Phys Anthropol 111:519\u2013530. https:\/\/doi.org\/10.1002\/(SICI)1096-8644(200004)111:4%3c519::AID-AJPA7%3e3.0.CO;2-7","journal-title":"Am J Phys Anthropol"},{"key":"1560_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jbmr.2325","volume":"30","author":"KES Poole","year":"2015","unstructured":"Poole KES et al (2015) Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. J Bone Miner Res 30:46\u201354. https:\/\/doi.org\/10.1002\/jbmr.2325","journal-title":"J Bone Miner Res"},{"key":"1560_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19:307\u2013317. https:\/\/doi.org\/10.1038\/s41584-023-00935-3","journal-title":"Nat Rev Rheumatol"},{"key":"1560_CR38","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u20131199. https:\/\/doi.org\/10.1056\/NEJMoa030897","journal-title":"N Engl J Med"},{"key":"1560_CR39","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00198-020-05399-9","volume":"31","author":"YJ Chen","year":"2020","unstructured":"Chen YJ, Kung PT, Chou WY, Tsai WC (2020) Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan. Osteoporos Int 31:1555\u20131563. https:\/\/doi.org\/10.1007\/s00198-020-05399-9","journal-title":"Osteoporos Int"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01560-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-025-01560-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01560-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:17:34Z","timestamp":1766524654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-025-01560-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1560"],"URL":"https:\/\/doi.org\/10.1007\/s11657-025-01560-1","relation":{},"ISSN":["1862-3514"],"issn-type":[{"type":"electronic","value":"1862-3514"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the institutional review board of our institution (2023 AN0277).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"93"}}